Abattis Bioceuticals Gets Added to the Marijuana Index by MJIC
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2017) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce it has officially been added to The Marijuana Index, within the Biotechnology sector.
The North American Marijuana Index tracks the leading public cannabis companies operating in the United States and Canada and gives investors up to date, centralized news on the securities deemed to be well positioned within the multi-billion dollar cannabis industry. Selected companies must meet stringent trading guidelines including having a minimum market capitalization of $30 million and daily trading volumes of above $400K.
"We are delighted to have Abattis added to the The Marijuana Index and look forward to sharing our story with investors closely tracking this exciting sector," stated Abattis CFO, Rene David. "As we approach sector legalization, we'll start to see markets broaden their reach from the closely covered cultivation and growing players to those advancing the technology and biosciences side of the cannabis industry," added Mr. David.
Abattis' subsidiary Northern Vine Labs is set to open its doors this month and will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the ACMPR regulatory framework. Management will continue to provide timely updates on these developments in the coming weeks.
About Abattis Bioceuticals Corp.
Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian Cannabis market.
Rene David, CFO, Director
For further information, contact the Company at (604) 336-0881 or at email@example.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.